Business
Reviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual Meeting
CUPERTINO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present a late-breaking poster presentation on the RECOVER 12-month open label extensio
About this update from Reviva Pharmaceuticals Holdings, Inc.
[{"type":"image","alt":"Reviva Pharmaceuticals","displaySize":"","headline":null,"caption":"Reviva Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/41c0f5cc737db653c49d46fe5ad892c8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/D8sDX1mL7wV8j6M4A9rWcA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/41c0f5cc737db653c49d46fe5ad892c8","width":300,"height":138}},"lazy":false},{"type":"text","content":"CUPERTINO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present a late-breaking poster presentation on the RECOVER 12-month open label extension trial for brilaroxazine in schizophrenia at the 2025 American Society of Clinical Psychopharmacology (ASCP) annual meeting, taking place May 27-30, 2025, in Scottsdale, AZ.","length":674,"tagName":"p"},{"type":"text","content":"Details for the poster presentation can be found below:","length":55,"tagName":"p"},{"type":"text","content":"Title: Brilaroxazine’s Effects on Efficacy, Safety, Adherence, and Biomarkers in the Phase 3 Recover 12-Month Open-Label Trial Extension in Patients with Stable SchizophreniaDate: Wednesday, May 28, 2025Time: 11:15 a.m. – 1 p.m. MTPresenter: Laxminarayan Bhat, Reviva PharmaceuticalsLocation: Fairmont Scottsdale Princess, Scottsdale, AZ","length":341,"tagName":"p"},{"type":"text","content":"Abstract and additional details are available on the 2025 ASCP annual meeting website.","length":86,"tagName":"p"},{"type":"text","content":"About Reviva Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP12...